
News|Articles|November 15, 2016
- Pharmaceutical Technology-11-15-2016
- Volume 2016 eBook
- Issue 3
Paperless Batch Records for the Masses
Author(s)Agnes Shanley
In InstantGMP, cloud-based IT and an approach grounded in cGMPs, brings more of the power of paperless recordkeeping to manufacturers, at a fraction of the cost.
Advertisement
CEO Rick Soltero, who worked In quality, manufacturing and R&D before establishing the company, talks about the challenges facing small-to-mid-sized pharma companies in modernizing their recordkeeping systems, and how important it is that solutions be grounded in cGMPs.
Download Pharmaceutical Technology’s
.
Articles in this issue
about 10 years ago
Extending QMS to Contract Partnersabout 10 years ago
Investigation Effectiveness Drives Human Performance Excellenceabout 10 years ago
Is Global Regulatory Gridlock Slowing Modernization?about 10 years ago
Ensuring Quality in Pharmaceutical Raw Materialsabout 10 years ago
Microbiological Testing: Time is of the EssenceAdvertisement
Related to this article

The FDA approves durvalumab for bladder cancer and gefurulimab for myasthenia gravis, creating distinct ADC, biologic, and autoinjector production needs.

The FDA has shelved its National Priority Voucher pilot, leaving sponsors that built CMC and launch-readiness plans around 1- to 2-month reviews facing uncertain timelines.

FDA approved pimicotinib for TGCT based on a 56% response rate; its Project Orbis review signals tighter global launch planning for manufacturers.

The FDA approves asundexian, the first factor XIa inhibitor, cutting stroke risk 26% and setting a regulatory benchmark for factor XI drug developers.

No operator touches a CAR-T batch before demonstrating proficiency. Generative AI users should meet the same standard, and a higher one, because an AI error does not stay inside one batch.

The FDA grants accelerated approval to subcutaneous amivantamab for head and neck cancer, extending the IV-to-subcutaneous shift in biologics formulation.

USP data show fewer US drug shortages but longer ones, averaging 5+ years. Drug shortages are an incentive problem, not a manufacturing mystery.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Signs Point to FDA Shelving Priority Voucher Pilot, Stalling Fast-Track Drug Reviews
2
AstraZeneca Secures 2 FDA Approvals in Bladder Cancer, Myasthenia Gravis
3
New Proposals and Legislation Strengthen Europe’s Position in the Pharmaceutical Arena
4
Manufacturing Intelligence: AI Poisoning Demands Pharma Data Stewards
5



